SecBot SecBot
PRESS-RELEASE ·Filed Mar 26, 2026

BWAY

BrainsWay
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Activist
Actionable Insight ▲ Bullish

Monitor Neurolief's commercial ramp, especially VA adoption and revenue traction, which could trigger the next $5M investment and increase acquisition likelihood. BrainsWay's valuation may re-rate if Proliv™Rx gains rapid market penetration.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.49
T+0 close · Mar 26, 2026 · via day close
Latest settled
+3.04%
T+60 · $13.90
Vs SPY
−10.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 26 $13.49entry
  2. T+1 · 8mo ago −4.60%α −2.92% · $12.87
  3. T+5 · 8mo ago +0.59%α −1.04% · $13.57
  4. T+20 · 7mo ago +21.35%α +10.68% · $16.37
  5. T+60 · 5mo ago +3.04%α −10.91% · $13.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BrainsWay completed a $6 million milestone-based convertible loan to Neurolief following FDA approval of Neurolief's Proliv™Rx system for treatment-resistant depression. The investment expands BrainsWay's strategic reach into at-home neurostimulation, complementing its in-clinic Deep TMS™ technology, with potential for further funding and an option to acquire Neurolief outright.

Key Financial Metrics

Deal Value
$6.0M

Key Facts

  • BrainsWay disbursed an additional $6 million convertible loan to Neurolief, triggered by FDA PMA approval of Proliv™Rx for MDD.
  • Total investment in Neurolief now stands at $11 million, with a potential additional $5 million equity tranche tied to revenue performance.
  • BrainsWay holds a call option to acquire all of Neurolief based on enterprise value or revenue multiple, depending on exercise timing.
  • Neurolief’s Proliv™Rx is the first FDA-approved at-home neurostimulation device for treatment-resistant depression.
  • Proliv™Rx and Relivion®MG are now included in the VA Federal Supply Schedule, enabling access to the VA health system.

Financial Impact

$6 million immediate outflow, $5 million potential future equity investment, total strategic exposure up to $16 million

cashstrategic investment valuefuture dilution risktotal addressable market expansion

Risk Factors

  • Execution risk in Neurolief's commercialization of Proliv™Rx
  • Potential future dilution if convertible debt converts or acquisition occurs
  • Regulatory or reimbursement challenges for at-home neurostimulation

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3262880

US Market Status

Market Closed · Opens Tue (16h 42m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 26, 2026